Core Points - Voyager Acquisition Corporation has successfully approved the business combination with VERAXA Biotech AG, which is expected to trade on Nasdaq under the new symbol "VRXA" after closing [1][3] - A significant redemption of approximately 99.67% of the total Class A shares outstanding occurred, with 25,217,315 Class A shares submitted for redemption, leaving approximately $885,556 in the trust account post-redemption [1] - Following the completion of the business combination, 82,685 Class A shares will convert into shares of the combined entity, Veraxa Biotech Holding AG [1] Company Overview - Voyager Acquisition Corporation is a special purpose acquisition company focused on revolutionizing the healthcare sector through mergers and business combinations, supported by a team with extensive expertise in investing and medical innovation [6] - VERAXA Biotech AG is dedicated to developing next-generation antibody-based therapeutics, including bispecific ADCs and T cell engagers, leveraging transformative technologies and quality-by-design principles [4]
Voyager Acquisition Corporation Announces Approval of Its Business Combination with Veraxa Biotech AG